Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 3, 2004, Pages 230-236

  Takigawa, Nagio ^a,b   Segawa, Yoshihiko ^a   Kishino, Daizo ^a,c   Fujiwara, Keiichi ^a,c   Tokuda, Yoshiyuki ^a,c   Seki, Nobuhiko ^a   Shinkai, Tetsu ^a   Watanabe, Yoichi ^d   Hiraki, Shunkichi ^d   Kozuki, Toshiyuki ^c   Gemba, Kenichi ^c   Tabata, Masahiro ^c   Kiura, Katsuyuki ^c   Ueoka, Hiroshi ^c   Tanimoto, Mitsune ^c  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b National Hospital Organization   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d Japanese Red Cross Okayama Hospital   (Japan)

Author keywords

Docetaxel; Elderly; Non small cell lung cancer; Pharmacokinetics; Symptom control assessment

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; FEVER; HUMAN; HYPOXEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOM; VOMITING;

EID: 4344602544     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0826-x     Document Type: Article

References (18)

1. Balducci L, Extermann M (1997) Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 80:1317-1322
2. Bunn PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087-1100
3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 30:2061-2067
4. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14:1649-1655
5. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8:355-363
6. Lichtman SM, Villani G (2000) Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 7:548-556
7. Marre F, Sanderink G, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
8. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
9. 2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48:356-360
10. National Cancer Institute - Common Toxicity Criteria, version 2.0: the Japan Clinical Oncology Group version (1999) Gan To Kagaku Ryoho 26:1084-1144
11. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
12. Oshita F, Kurata T, Kasai T, Fakuda M, Yamamoto N, Ohe Y, Tamura T, Eguchi K, Shinkai T, Saijo N (1995) Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86:1198-1202
13. Segawa Y, Watanabe K, Hiraki S, Tominaga K, Hayashi I, Harada M, Yamakido M, Ueda N, Kashimura I, Niitani H (2000) Phase I study of docetaxel and cisplatin for patients with previously untreated metastatic non-small-cell lung cancer: a Japanese cooperative study. Int J Clin Oncol 5:308-315
14. Sobue T (2001) Lung cancer. Gan To Kagaku Ryoho 28:163-167
15. Taguchi T, Furue H, Niitani H, Ishitani K, Kanamaru R, Hasegawa K, Ariyoshi Y, Noda K, Furuse K, Fukuoka M (1994) Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho 21:1997-2005
16. Takigawa N, Segawa Y, Kishino D, Fujiwara K, Ida M, Eguchi K (2000) Combination chemotherapy consisting of ifosfamide and vindesine for non-small cell lung cancer in the elderly. Nippon Kokyuki Gakkai Zasshi 38:273-277
17. The Elderly Lung Cancer Vinorelbine Italian Study group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72
18. Yoshimi I, Ohshima A, Ajiki W, Tsukuma H, Sobue T (2003) A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. Jpn J Clin Oncol 33:98-104